Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-1.11 Insider Own1.90% Shs Outstand87.62M Perf Week2.76%
Market Cap2.61B Forward P/E106.43 EPS next Y0.28 Insider Trans-41.82% Shs Float70.05M Perf Month21.88%
Income-99.10M PEG- EPS next Q-0.16 Inst Own55.20% Short Float4.17% Perf Quarter44.66%
Sales194.30M P/S13.44 EPS this Y29.30% Inst Trans12.34% Short Ratio3.11 Perf Half Y64.19%
Book/sh1.18 P/B25.25 EPS next Y145.20% ROA-23.70% Target Price31.20 Perf Year156.90%
Cash/sh2.47 P/C12.07 EPS next 5Y60.00% ROE-56.70% 52W Range11.50 - 30.25 Perf YTD47.52%
Dividend- P/FCF- EPS past 5Y- ROI-41.40% 52W High-1.49% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin68.00% 52W Low159.13% ATR1.01
Employees495 Current Ratio6.30 Sales Q/Q49.30% Oper. Margin-19.90% RSI (14)69.92 Volatility3.17% 3.50%
OptionableYes Debt/Eq1.41 EPS Q/Q-11.60% Profit Margin-33.10% Rel Volume0.73 Prev Close29.70
ShortableYes LT Debt/Eq1.41 EarningsApr 26 BMO Payout- Avg Volume938.85K Price29.80
Recom1.60 SMA205.28% SMA5021.61% SMA20040.29% Volume682,715 Change0.34%
Apr-18-18Reiterated Mizuho Buy $28 → $32
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-27-15Initiated Wedbush Outperform
Oct-27-15Initiated JP Morgan Overweight
Oct-27-15Initiated JMP Securities Mkt Outperform $43
May-14-18 12:02PM  Best Growth Stock in May Simply Wall St.
May-11-18 11:46AM  Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-18 04:53PM  This Explains Why NovoCure Is Surging Today Motley Fool +9.73%
11:55AM  NovoCure: 1Q Earnings Snapshot Associated Press
06:00AM  Novocure Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Apr-25-18 11:10AM  NovoCure (NVCR) Shares March Higher, Can It Continue Zacks
Apr-19-18 08:00AM  Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.04%
07:10AM  Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma ACCESSWIRE
Apr-18-18 08:31AM  NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session Zacks
Apr-17-18 07:30AM  Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Business Wire +7.89%
Apr-13-18 06:31PM  3 Top Healthcare Stocks to Buy in April Motley Fool
04:30PM  Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting Business Wire
Apr-03-18 12:23PM  Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet A Threat To Its Future? Simply Wall St.
07:30AM  Novocure to Report First Quarter 2018 Financial Results Business Wire
Mar-20-18 09:14AM  NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma Business Wire
Mar-19-18 07:00AM  Wired News NovoCure Announced Data Presentations on Tumor Treating Fields at AACR Annual Meeting 2018 ACCESSWIRE
Mar-15-18 05:42PM  Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR) Simply Wall St.
07:30AM  Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018 Business Wire
Mar-08-18 04:21PM  Edited Transcript of NVCR earnings conference call or presentation 22-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Feb-26-18 07:03PM  Cramer Remix: It's time to investigate risky VIX-related ... CNBC Videos +7.25%
07:02PM  Tumor-treating biotech Novocure turns its attention to lu... CNBC Videos
06:59PM  Cramer Remix: It's time to investigate risky VIX-related trading products CNBC
Feb-22-18 07:30AM  NovoCure reports 4Q loss Associated Press
06:00AM  Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Feb-13-18 05:19PM  Who Really Owns NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
Feb-09-18 07:55AM  Report: Exploring Fundamental Drivers Behind Vector Group, NovoCure, ORBCOMM, Adamis Pharmaceuticals, Calumet Specialty Products Partners, and Lakeland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-07-18 04:01PM  Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Business Wire
Feb-05-18 08:31AM  Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director GlobeNewswire
Feb-01-18 11:05AM  JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients Business Wire
Jan-16-18 06:15PM  Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares GuruFocus.com
Jan-09-18 10:53AM  Here's Why NovoCure Popped 157% in 2017 Motley Fool
07:30AM  Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue Business Wire
Dec-21-17 06:25PM  Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
06:00AM  3 Stocks That Could Put Amazon's Returns to Shame Motley Fool
Dec-20-17 07:30AM  Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-17 11:05AM  JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma Business Wire
Dec-18-17 07:37AM  Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer Business Wire
Dec-13-17 12:44PM  How Does NovoCure Limiteds (NASDAQ:NVCR) EPS Growth Stack Up Against Industry Performance? Simply Wall St.
Dec-11-17 08:17AM  Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
08:15AM  Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors GlobeNewswire
Dec-07-17 02:25PM  ETFs with exposure to Novocure Ltd. : December 7, 2017 Capital Cube
Dec-04-17 11:28AM  Novocure Ltd. Value Analysis (NASDAQ:NVCR) : December 4, 2017 Capital Cube -6.89%
11:20AM  Is NovoCure Limited (NVCR) Undervalued? Simply Wall St.
Dec-01-17 07:30AM  Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma Business Wire
07:13AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : December 1, 2017 Capital Cube
Nov-22-17 07:30AM  Novocure to Present at Two Upcoming Investor Conferences in December Business Wire
Nov-20-17 08:20AM  Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Nov-18-17 11:32AM  3 Top Medical Device Stocks to Buy Now Motley Fool
Nov-17-17 09:34AM  Estimating The Intrinsic Value Of NovoCure Limited (NVCR) Simply Wall St.
09:26AM  Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers TheStreet.com
07:30AM  Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocures EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent Business Wire
Nov-13-17 12:56PM  ETFs with exposure to Novocure Ltd. : November 13, 2017 Capital Cube
07:19AM  Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-09-17 07:00AM  Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-08-17 07:00AM  Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire -6.13%
Nov-06-17 10:00AM  3 Stocks Changing the Future of Healthcare Motley Fool
07:00AM  Novocure Announces Six Clinical Presentations on Novocures Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-01-17 12:16PM  Harry Boxers four stocks to watch this week MarketWatch
Oct-31-17 08:09AM  Novocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : October 31, 2017 Capital Cube +6.14%
Oct-30-17 12:07PM  ETFs with exposure to Novocure Ltd. : October 30, 2017 Capital Cube
Oct-27-17 06:06PM  Edited Transcript of NVCR earnings conference call or presentation 26-Oct-17 12:00pm GMT Thomson Reuters StreetEvents +5.71%
09:18AM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 27, 2017 Capital Cube
Oct-26-17 06:45AM  NovoCure reports 3Q loss Associated Press
06:00AM  Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update Business Wire
Oct-22-17 12:15PM  3 Healthcare Stocks for Your Radar Motley Fool
Oct-17-17 08:45AM  NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session Zacks
Oct-16-17 04:30PM  Why Rite Aid, Hudbay Minerals, and NovoCure Jumped Today Motley Fool +8.28%
07:30AM  Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer Business Wire
Oct-03-17 11:53AM  Novocure Ltd. Value Analysis (NASDAQ:NVCR) : October 3, 2017 Capital Cube
Oct-02-17 08:22AM  Novocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : October 2, 2017 Capital Cube
07:00AM  Novocure to Report Third Quarter 2017 Financial Results Business Wire
Sep-25-17 09:40AM  Intercept Spikes; Novocure Jumps on Phase 3 Data -Biotech Movers TheStreet.com
Sep-24-17 06:15PM  Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients Business Wire
Sep-22-17 07:00AM  Novocure Announces Data Presentations at the American Society for Radiation Oncologys 2017 Annual Meeting Business Wire
Sep-19-17 07:15AM  3 Innovation-Forward Healthcare Stocks to Buy Now Motley Fool
Sep-14-17 02:29PM  Dolby Laboratories is a stock to watch after Apples new iPhone launch MarketWatch
Sep-06-17 07:00AM  Novocure Announces Data Presentations at the ESMO 2017 Congress Business Wire
Sep-05-17 07:41AM  German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma Business Wire
Aug-28-17 08:23AM  If You Love Intuitive Surgical, You Should Check Out This Small-Cap Growth Stock Motley Fool
Aug-24-17 07:00AM  Novocure to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-22-17 02:21PM  Edited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-16-17 06:00AM  3 Stocks That Could Soar More Than Priceline Motley Fool
Aug-15-17 09:01PM  3 Game-Changing Small-Cap Healthcare Stocks Motley Fool
Aug-11-17 06:10PM  ETFs with exposure to Novocure Ltd. : August 11, 2017 Capital Cube
Aug-08-17 09:25AM  Novocure Announces National Reimbursement for Optune® in Austria Business Wire +5.23%
Aug-02-17 05:31PM  3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment Motley Fool
07:00AM  Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-17 10:07AM  3 Hot Healthcare Stocks Under $30 Motley Fool
Jul-28-17 12:38PM  Novocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
12:28AM  NovoCure reports 2Q loss Associated Press
Jul-27-17 06:15AM  Investor Network: Novocure Ltd. to Host Earnings Call ACCESSWIRE +5.97%
06:00AM  Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
Jul-24-17 07:22AM  Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma Business Wire
Jul-20-17 06:21PM  Many treatment options, most experimental, available to John McCain Reuters
Jul-18-17 08:16AM  These 2 Companies Have No Competition Motley Fool
Jul-13-17 06:07AM  The Fastest Growing Cancer Company You've Never Heard Of Motley Fool
Jul-12-17 08:47AM  NovoCure (NVCR) Jumps: Stock Rises 10.5% Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. Accesswire
Markets a wearable electric field device for treating glioblastoma brain cancer.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEUNG GABRIELDirectorMay 16Option Exercise3.44100,000344,000100,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 16Sale28.7740,0001,150,80060,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 15Option Exercise3.4440,000137,60040,000May 17 04:18 PM
LEUNG GABRIELDirectorMay 15Sale28.8840,0001,155,2000May 17 04:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 14Sale30.0521,077633,411178,121May 15 04:26 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 11Sale30.019,393281,858199,198May 15 04:26 PM
Ambrogi Michael J.Chief Operating OfficerMay 01Option Exercise3.4428,69598,711175,253May 03 04:34 PM
Ambrogi Michael J.Chief Operating OfficerMay 01Sale27.4060,0001,644,000146,558May 03 04:34 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMay 01Sale27.5830,470840,363208,591May 03 04:30 PM
Ambrogi Michael J.Chief Operating OfficerApr 26Option Exercise3.4420,00068,800166,558Apr 30 05:56 PM
Ambrogi Michael J.Chief Operating OfficerApr 26Sale26.0120,000520,142146,558Apr 30 05:56 PM
Palti YoramChief Technology OfficerApr 26Sale26.0920,966547,0131,161,054Apr 30 05:03 PM
Palti YoramChief Technology OfficerApr 24Sale25.065,600140,3201,182,020Apr 25 04:08 PM
Palti YoramChief Technology OfficerApr 23Sale25.0730,000751,9621,187,620Apr 25 04:08 PM
Palti YoramChief Technology OfficerApr 20Sale25.0619,362485,1831,217,620Apr 23 04:05 PM
Palti YoramChief Technology OfficerApr 19Sale24.9330,000748,0421,236,982Apr 23 04:05 PM
Ambrogi Michael J.Chief Operating OfficerApr 18Option Exercise3.4420,00068,800166,558Apr 19 04:54 PM
Kirson Eilon D.Chief Science OfficerApr 18Option Exercise3.44147,825508,518116,451Apr 20 04:53 PM
Kirson Eilon D.Chief Science OfficerApr 18Sale24.00147,8253,547,80039,582Apr 20 04:53 PM
Ambrogi Michael J.Chief Operating OfficerApr 18Sale24.0020,000480,000146,558Apr 19 04:54 PM
Palti YoramChief Technology OfficerApr 18Sale24.1014,072339,0801,266,982Apr 19 04:21 PM
Ambrogi Michael J.Chief Operating OfficerApr 17Option Exercise3.4420,00068,800166,558Apr 19 04:54 PM
Ambrogi Michael J.Chief Operating OfficerApr 17Sale22.0620,000441,240146,558Apr 19 04:54 PM
Palti YoramChief Technology OfficerApr 17Sale23.4430,000703,2241,281,054Apr 19 04:21 PM
Palti YoramChief Technology OfficerApr 04Sale19.8930,000596,7541,311,054Apr 05 04:17 PM
Palti YoramChief Technology OfficerApr 03Sale20.1930,000605,5681,341,054Apr 04 04:05 PM
Palti YoramChief Technology OfficerApr 02Sale20.4630,000613,8611,371,054Apr 04 04:05 PM
Palti YoramChief Technology OfficerMar 29Sale21.6730,000649,9771,401,054Apr 02 04:05 PM
Ambrogi Michael J.Chief Operating OfficerMar 19Option Exercise0.2349,72811,437146,558Mar 20 04:37 PM
Longsworth Todd ChristopherGeneral CounselFeb 23Sale19.836,591130,68620,074Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 23Sale19.838,458167,70596,830Feb 26 05:13 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 23Sale19.8313,351264,724239,061Feb 26 05:09 PM
Longsworth Todd ChristopherGeneral CounselFeb 22Option Exercise21.5521,667466,92426,665Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 22Option Exercise21.5531,201672,382105,288Feb 26 05:13 PM
Danziger AsafChief Executive OfficerFeb 22Option Exercise21.5553,3341,149,348410,124Feb 26 05:11 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 22Option Exercise21.5543,334933,848252,412Feb 26 05:09 PM
Kirson Eilon D.Chief Science OfficerFeb 22Option Exercise21.5536,401784,44239,582Feb 26 05:10 PM
Ambrogi Michael J.Chief Operating OfficerFeb 06Option Exercise0.2350,00011,50074,087Feb 08 04:14 PM
Longsworth Todd ChristopherGeneral CounselJan 29Option Exercise6.7211,63078,15416,628Jan 31 04:29 PM
Longsworth Todd ChristopherGeneral CounselJan 29Sale24.0011,630279,1204,998Jan 31 04:29 PM
Danziger AsafChief Executive OfficerJan 29Sale24.0213,974335,588356,790Jan 31 04:22 PM
Danziger AsafChief Executive OfficerJan 25Sale22.436,456144,840370,764Jan 26 04:14 PM
Danziger AsafChief Executive OfficerJan 24Sale22.1710,600235,007377,220Jan 25 04:26 PM
Danziger AsafChief Executive OfficerJan 23Sale22.0310,248225,794387,820Jan 25 04:26 PM
DOYLE WILLIAM FExecutive ChairmanJan 22Option Exercise3.591,5495,56192,746Jan 24 04:18 PM
Danziger AsafChief Executive OfficerJan 16Sale22.2014,900330,755398,068Jan 17 05:05 PM
Danziger AsafChief Executive OfficerJan 12Sale22.0222,895504,237412,968Jan 16 05:00 PM
Kirson Eilon D.Chief Science OfficerJan 11Sale22.0025,320557,1263,181Jan 16 05:01 PM
Danziger AsafChief Executive OfficerJan 11Sale22.35313,5257,007,503435,863Jan 16 05:00 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 09Sale21.0231,132654,376209,078Jan 10 04:11 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 04Sale21.0326,264552,314239,900Jan 05 04:06 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 03Sale21.002,60454,689266,164Jan 05 04:06 PM
Palti YoramChief Technology OfficerNov 13Sale17.1330,000513,8701,431,054Nov 14 04:25 PM
Palti YoramChief Technology OfficerNov 10Sale17.6130,000528,1501,461,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 09Sale18.2530,000547,4331,491,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 08Sale19.6130,000588,2491,521,054Nov 13 04:36 PM
Palti YoramChief Technology OfficerNov 07Sale20.4230,000612,5201,551,054Nov 08 04:17 PM
Palti YoramChief Technology OfficerNov 06Sale21.7130,000651,2401,581,054Nov 08 04:17 PM
Kirson Eilon D.Chief Science OfficerNov 06Sale22.009,100200,20028,501Nov 08 04:15 PM
Danziger AsafChief Executive OfficerNov 06Sale22.006,919152,218749,105Nov 08 04:14 PM
Palti YoramChief Technology OfficerNov 03Sale21.6630,000649,6801,611,054Nov 06 04:22 PM
Kirson Eilon D.Chief Science OfficerNov 03Sale22.003,10068,20037,601Nov 06 04:18 PM
Ambrogi Michael J.Chief Operating OfficerNov 03Sale22.0090019,80024,087Nov 06 04:17 PM
Danziger AsafChief Executive OfficerNov 03Sale22.002,30050,600756,024Nov 06 04:15 PM
Palti YoramChief Technology OfficerNov 02Sale21.7830,000653,5201,641,054Nov 06 04:22 PM
Kirson Eilon D.Chief Science OfficerNov 02Sale22.003006,60040,701Nov 06 04:18 PM
Ambrogi Michael J.Chief Operating OfficerNov 02Sale22.003006,60024,987Nov 06 04:17 PM
Danziger AsafChief Executive OfficerNov 01Sale22.0115,716345,870758,324Nov 02 04:20 PM
Kirson Eilon D.Chief Science OfficerNov 01Sale22.0122,119486,81041,001Nov 02 04:22 PM
Ambrogi Michael J.Chief Operating OfficerNov 01Sale22.0124,227533,16425,287Nov 02 04:19 PM
Danziger AsafChief Executive OfficerOct 31Sale22.001503,300774,040Nov 02 04:20 PM
Kirson Eilon D.Chief Science OfficerOct 31Sale22.001503,30063,120Nov 02 04:22 PM
Ambrogi Michael J.Chief Operating OfficerOct 31Sale22.001002,20049,514Nov 02 04:19 PM
Danziger AsafChief Executive OfficerSep 25Sale22.0590019,845774,190Sep 27 04:18 PM
Danziger AsafChief Executive OfficerSep 14Sale22.001,77238,984775,090Sep 15 04:05 PM
Danziger AsafChief Executive OfficerSep 13Sale22.0135,500781,518776,862Sep 15 04:05 PM
Danziger AsafChief Executive OfficerJul 14Option Exercise0.38354,780134,816812,362Jul 18 04:48 PM
Danziger AsafChief Executive OfficerJul 11Sale19.957,383147,325457,582Jul 13 04:14 PM
Danziger AsafChief Executive OfficerJul 10Sale18.08203,9003,685,900464,965Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 07Sale18.0370,4591,270,658668,865Jul 11 04:22 PM
Danziger AsafChief Executive OfficerJul 06Sale18.095,05091,344739,324Jul 07 04:33 PM
Danziger AsafChief Executive OfficerJul 05Sale18.14155,0882,813,917744,374Jul 07 04:33 PM
Pomona Capital VII, L.P.10% OwnerJun 26Sale17.4699,3411,734,1862,741,925Jun 27 04:11 PM
Pomona Capital VII, L.P.10% OwnerJun 23Sale17.34973,19116,872,8942,772,870Jun 27 04:11 PM
Kirson Eilon D.Chief Science OfficerJun 21Sale16.7866,3611,113,206222,722Jun 22 04:29 PM
Kirson Eilon D.Chief Science OfficerJun 19Sale15.0615,000225,885289,083Jun 21 04:19 PM
Danziger AsafChief Executive OfficerJun 19Sale15.51124,7201,934,906896,917Jun 21 04:17 PM
Danziger AsafChief Executive OfficerJun 16Sale15.029,212138,3461,021,637Jun 19 04:31 PM
Danziger AsafChief Executive OfficerJun 15Sale15.1933,245504,8921,030,849Jun 19 04:31 PM
DOYLE WILLIAM FDirectorJun 14Option Exercise3.596,49823,32891,197Jun 15 04:23 PM
Danziger AsafChief Executive OfficerJun 14Sale15.015,40281,0681,064,094Jun 15 04:17 PM
Kirson Eilon D.Chief Science OfficerJun 13Sale15.019,044135,769304,083Jun 15 04:28 PM
Danziger AsafChief Executive OfficerJun 13Sale15.2388,7001,351,0781,069,496Jun 15 04:17 PM
Danziger AsafChief Executive OfficerJun 12Sale15.095,10076,9341,158,196Jun 13 06:35 PM
Kirson Eilon D.Chief Science OfficerJun 12Sale15.085,95689,828313,127Jun 13 06:19 PM
Danziger AsafChief Executive OfficerJun 09Sale15.13175,5012,654,9791,163,296Jun 13 06:35 PM
Kirson Eilon D.Chief Science OfficerJun 09Sale15.0215,000225,225319,083Jun 13 06:19 PM
Palti YoramChief Technology OfficerJun 05Sale13.823,82552,8420Jun 06 05:17 PM
Palti YoramChief Technology OfficerJun 02Sale13.494,00053,9563,825Jun 05 04:19 PM
Palti YoramChief Technology OfficerJun 01Sale13.054,00052,1847,825Jun 05 04:19 PM